Why the study?
Whether low-dose new generation P2Y12 receptor antagonists are more suitable than standard-dose clopidogrel in DAPT for East Asian patients receiving PCI lacked consensus in clinical practice.
Does low-dose ticagrelor or prasugrel reduce MACEs without increasing bleeding compared to standard-dose clopidogrel in East Asian patients undergoing PCI?
Population
2,747 East Asian patients undergoing PCI across 8 RCT studies
Comparison
Low-dose P2Y12 receptor antagonists vs standard-dose clopidogrel
Design
Systematic review and meta-analysis of RCTs
Authors
Loading...
Supports low-dose ticagrelor or prasugrel over clopidogrel in East Asian PCI patients; extends evidence for ethnicity-specific P2Y12 dosing.
Does low-dose ticagrelor or prasugrel reduce MACEs without increasing bleeding compared to standard-dose clopidogrel in East Asian patients undergoing PCI?
In East Asian patients undergoing PCI, low-dose ticagrelor or prasugrel provides superior efficacy in reducing MACEs compared to standard-dose clopidogrel without increasing bleeding risk.
Hu et al. (2021) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: